Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Risklick’s Protocol AI is an end-to-end AI software product for developing clinical trial protocols and study plans. Its core goal is to help experts produce high-quality protocols and study plans faster, thereby shortening the clinical development cycle. The official website claims it can reduce protocol and study plan development time by 50%, protocol amendments by 20%, and protocol implementation time by 40%, though no third-party validation details are provided.
The product workflow is divided into three steps: Explore, Design, and Develop. It first systematically analyzes research design elements, then generates multiple design scenarios for optimization, and finally uses customized generative AI to create protocols and study plans. A key differentiator is its database of more than 800,000 clinical trials, linked with publications, regulatory approvals, safety data, and other sources, making it well suited for evidence-driven protocol design. It also supports digital protocols based on ICH M11 and USDM standards, can adapt to different protocol templates, and can export to Word, Excel, and JSON.
Protocol AI can integrate with electronic clinical trial systems such as EDC and eTMF to improve protocol implementation and change management efficiency. Its terms state that it complies with GDPR and holds ISO 27001:2022 information security management compliance. Materials uploaded by customers remain the property of the customer, but the platform is authorized to use them to provide and improve the service. For support, the official website promises 24/7 assistance via a ticketing system and [email protected], with a maximum response time of 24 hours.
The website does not publish pricing, free quotas, or trial options; it only offers Request a Demo. The terms indicate that it uses a subscription model, with fees prepaid according to the subscription plan and potentially limited by number of users, duration, and available features. Its limitations include a lack of disclosure around the underlying model, AI output validation mechanisms, Chinese-language support, and adaptability to Chinese regulations. It also has a relatively high professional barrier and is not suitable for ordinary individual users.
It is better suited to pharmaceutical companies, CROs, clinical operations teams, medical writing teams, and quality/regulatory teams, especially organizations that need standardized, evidence-based, and digital protocol management. The scraped text does not provide information on access from China, so this remains unknown for now; payment methods are also not disclosed. For deployment in China, key points to confirm include network accessibility, contract and cross-border data compliance, payment methods, and integration capabilities with local EDC/eTMF systems. Alternatives worth considering include Veeva, Medidata, Oracle Clinical One, or domestic clinical trial digitization platforms.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on risklick.ch official site.
risklick.ch is an Switzerland AI Apps provider. TG4G tracks its product information, an overall rating of 8.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach risklick.ch directly.